Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Deferred Tax Liability (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $4.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 24.86% to $4.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.4 million, a 24.86% increase, with the full-year FY2024 number at $4.4 million, changed N/A from a year prior.
  • Non-Current Deferred Tax Liability was $4.4 million for Q3 2025 at Century Therapeutics, roughly flat from $4.4 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.4 million in Q4 2024 to a low of $5000.0 in Q4 2022.
  • A 3-year average of $3.5 million and a median of $4.4 million in 2024 define the central range for Non-Current Deferred Tax Liability.
  • Biggest YoY gain for Non-Current Deferred Tax Liability was 29.95% in 2025; the steepest drop was 24.86% in 2025.
  • Century Therapeutics' Non-Current Deferred Tax Liability stood at $5000.0 in 2022, then surged by 87380.0% to $4.4 million in 2024, then changed by 0.0% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Non-Current Deferred Tax Liability are $4.4 million (Q3 2025), $4.4 million (Q2 2025), and $4.4 million (Q1 2025).